Treviamet XR
Therapeutic Segment:
Anti-diabetic
Generic Name:
Sitagliptin phosphate monohydrate + Metformin HCl
Indication
Extended Release Tablets
- 50MG + 500MG
- 50MG + 1000MG
- Initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control, when dual sitagliptin and metformin HCl therapy is appropriate (i.e, high initial HbA1c levels and poor prospects of response to monotherapy)
- As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on Metformin HCl or Sitagliptin alone or in patients already being treated with the combination of Sitagliptin and Metformin HCl
- In combination with a sulphonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus when combination therapy with metformin HCl and sulphonylurea does not provide adequate glycemic control
- As an adjunct to diet and exercise to improve glycemic control in combination with insulin in patients with type 2 Diabetes mellitus inadequately controlled on insulin and metformin HCl or in patients already being treated with the combination of sitagliptin, metformin HCl and insulin.